New Blood Biomarker to Detect Early Dementia?
A unique ratio of metabolites measured in blood may help supplement a clinical diagnosis of early Alzheimer's disease, allowing for earlier intervention, early research suggests. Investigators found that plasma concentrations of 2-aminoethyl dihydrogen phosphate and taurine could distinguish adults with early-stage Alzheimer's disease from cognitively normal adults.
@miraj The researchers measured concentrations of 2-aminoethyl dihydrogen phosphate and taurine in blood plasma samples in 25 patients (21 men; mean age, 71) with a clinical diagnosis of early-stage Alzheimer's based on a Clinical Dementia Rating (CDR) score of 0.5, suggesting very mild cognitive impairment, and 25 healthy controls (20 men; mean age, 39). The concentration of 2-aminoethyl dihydrogen phosphate, normalized by the concentration of taurine, reliably distinguished blood samples of early-stage Alzheimer's patients from controls in a blinded analysis. This biomarker "could lead to new understanding of AD disease and lead to new drug candidates," Banack told Medscape Medical News. The researchers note that 2-aminoethyl dihydrogen phosphate plays an important role in the structure and function of cellular membranes.